Probiotic composition for use in the treatment of bowel inflammation

Abstract

The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, or abdominal distension and bloating.

Description

[0001]This application claims the benefit of the U.S. provisional application No. 61 / 299,116, and of the European patent application EP10151998, both filed on 28 Jan. 2010, and which are incorporated herein by reference.[0002]The present invention relates to the fields of medicine, microbiology and nutrition and, particularly, to a novel probiotic composition. Particularly, new strains of Lactobacillus plantarum and Pediococcus acidilactici have been isolated and combined in a formulation useful in the treatment of gastrointestinal diseases, such as bowel inflammation (e.g., inflammatory bowel disease) and irritable bowel syndrome.BACKGROUND OF THE INVENTION[0003]Ulcerative colitis (UC), Pouchitis, and Crohn's Disease are examples of Inflammatory Bowel Diseases (IBD) characterized by chronic inflammation in the intestine. The clinical symptoms are diarrhea, abdominal pain, occasional rectal bleeding, weight loss, tiredness and sometimes fever. Although occurring at any age, IBD is m...

AI Technical Summary

Benefits of technology

[0086]The therapeutic effect of the composition of the invention on mild gut inflammation was investigated with a 5-day repetitive oral administration of dextran sodium sulfate (DSS) in the mouse (Okayasu I. et al., 1990). When used in a low dose (2.5-3%) for a short time (5 days), DSS produces mild colitis, with intestinal inflammation at the histological level but without significant macroscopic changes (e.g. colon shortening, mesenteric adherences).

[0087]External symptoms include weight loss and diarrhea, with rare occurrence of blood in feces. Therefore this model is representative of low-grade ulcerative colitis.

[0088]Strains F1033, F2064 and F2076 were lyophilised in sterile water with 15% skim milk and 4% sucrose as cryoprotectants and mixed in equal amounts (ratio in concentration 1:1:1).

[0089]Eight-week-old Balb/c mice (Charles River, Barcelona, Spain), weighing 20-25 g, were kept under specific pathogen-free (SPF) conditions in an isolator (Harlan Iberica, Barcelona, Spain) at constant temperature (22° C.) in a 12-hour of light/dark cycle. Two mice acted as littermates.

Problems solved by technology

Although occurring at any age, IBD is most common in teenagers and young adults, which consequently may suffer from delayed development and stunted growth.

However, there is currently no medical cure for IBD.

Coloectomy may eliminate UC but reduces life quality and increases the risk of complications.

Diarrhea or abdominal pain appear as side effects of 5-ASA whereas long term use of corticosteroids frequently shows serious side effects includ

Images